Luv Patel

1 Introduction Lipid nanoparticles (LNPs) have revolutionized the field of nucleic acid delivery and have been extensively explored in gene therapy, protein replacement therapies, and immunotherapies for various diseases.[1-3] Their clinical applications were notably demonstrated by their widespread use in delivering the SARS-CoV-2 vaccine during the COVID-19 pandemic.[4-7] Despite their promise, targeting beyond the liver remains a significant challenge with the traditional LNPs, which are...

Abstract Lipid nanoparticles (LNPs) hold transformative potential for nucleic acid delivery, with applications ranging from clinical use, particularly in COVID-19 vaccines, to gene therapy and cancer immunotherapy. Traditional LNPs are composed of four components: ionizable lipids, cholesterol, helper lipids, and PEGylated lipids.